pimobendan

Pimobendan is a benzimidazole-pyridazinone derivative classified as an inodilator, used primarily in veterinary medicine for the management of congestive heart failure (CHF) in dogs. Its main indications are for CHF due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), and it is also approved to delay the onset of CHF in dogs with preclinical MMVD. Pimobendan acts through a dual mechanism of action: it increases myocardial contractility by sensitizing cardiac troponin C to calcium and inhibits phosphodiesterase III (PDE3), resulting in vasodilation. This combination leads to increased cardiac output and reduced preload and afterload without significantly increasing myocardial oxygen consumption. The drug is administered orally, most commonly as tablets, but can also be given as an oral liquid or injection depending on regional availability[1][3][5][7].

Brand names

Vetmedin